Cytokinetics (CYTK)

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Osakkeen Cytokinetics, Incorporated Common Stock (CYTK) hinta tänään on eli muutosta on ollut epäluku % siitä, kun markkina avattiin. Yrityksen markkina-arvo on 7,45 mrd. $, ja päivittäisen kaupankäynnin määrä on  osaketta. Edellinen sulkemishinta oli .

Aloitetaanko? Seuraa alla olevia vaiheita tai lue oppaamme siitä, miten ostaa Cytokinetics osakkeita Krakenista alkaen 10 dollarista.